IMNR - Immune Response Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: BLUE HORSE SHOE who wrote (353)	4/5/1998 11:28:00 PM
From: Easy Mark	Read Replies (1) of 1510

BHS: Thanks for the Yahoo posts. How do I locate them directly? The respondent you copy makes some excellent points. I want to extend his comment on "the large drug companies move at their own pace". In fact, most of the majors have a portfolio of R&D opportunities that include "Remune equivalents" in the sense that they are 10:1 or better payoffs. In the current issue of HBR, Smith Kline Beecham describes its cutoff as 5:1. The implication for small biotechs is that, in seeking partnerships, they are competing against internal options that are pretty stiff competition for funds. As a consequence, they have to give up a 5:1 payoff in order to gain funding. I take issue with the responent's notion that the DSRB will make a call based solely on the Remune interim data. IMHO the NEJM article is a big change in the sea swell. It is not likely to be ignored. I think it is a real positive for Remune that they have four separate phase II combination trials scheduled for completion this year.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next